A cohort of 168 patients with IDH-1 mutated cholangiocarcinoma, chondrosarcoma, and glioma were treated with ivosidenib in order to evaluate pharmacokinetic and pharmacodynamics profiles. This evidence concerns the gene IDH1 and glioma.